Department of Precision Medicine, School of Medicine, University of Campania "Luigi Vanvitelli", Via De Crecchio 7, 80138, Naples, Italy.
S.S.D. Sperimentazione Animale, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Naples, Italy.
J Transl Med. 2023 Apr 21;21(1):273. doi: 10.1186/s12967-023-04110-w.
Early in the COVID-19 pandemic, it emerged that the risk of severe outcomes was greater in patients with co-morbidities, including cancer. The huge effort undertaken to fight the pandemic, affects the management of cancer care, influencing their outcome. Despite the high fatality rate of COVID-19 disease in cancer patients, rare cases of temporary or prolonged clinical remission from cancers after SARS-CoV-2 infection have been reported. We have reviewed sixteen case reports of COVID-19 disease with spontaneous cancer reduction of progression. Fourteen cases of remission following viral infections and two after anti-SARS-CoV-2 vaccination. The immune response to COVID-19, may be implicated in both tumor regression, and progression. Specifically, we discuss potential mechanisms which include oncolytic and priming hypotheses, that may have contributed to the cancer regression in these cases and could be useful for future options in cancer treatment.
在 COVID-19 大流行早期，患有合并症（包括癌症）的患者出现严重后果的风险更高。为抗击大流行所做的巨大努力影响了癌症治疗的管理，影响了其结果。尽管 COVID-19 疾病在癌症患者中的死亡率很高，但据报道，SARS-CoV-2 感染后癌症有暂时或长期临床缓解的罕见病例。我们回顾了 16 例 COVID-19 疾病伴有自发癌症进展减少的病例报告。14 例在病毒感染后缓解，2 例在抗 SARS-CoV-2 疫苗接种后缓解。COVID-19 的免疫反应可能与肿瘤消退和进展有关。具体而言，我们讨论了可能导致这些病例中癌症消退的潜在机制，包括溶瘤和启动假说，这些机制可能对未来癌症治疗的选择有用。
